和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

已收盘 03-25 16:08:03

7.930

-0.330

-4.00%

最高8.950	最低7.880	成交量1,526万
今开8.240	昨收8.260	日振幅12.95%
总市值60.03亿	流通市值60.03亿	总股本7.57亿
成交额1.29亿	换手率2.02%	流通股本7.57亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":7.93,"timestamp":1742890083014,"preClose":8.26,"halted":0,"volume":15262276,"delay":0,"floatShares":757000000,"shares":757000000,"eps":0.2415128376592072,"marketStatus":"已收盘","change":-0.33,"latestTime":"03-25 16:08:03","open":8.24,"high":8.95,"low":7.88,"amount":128509259,"amplitude":0.12954,"askPrice":7.93,"askSize":15000,"bidPrice":7.92,"bidSize":9000,"shortable":0,"etf":0,"ttmEps":0.21770368412049204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1742952600000},"marketStatusCode":5,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":8.26,"openAndCloseTimeList":[[1742866200000,1742875200000],[1742878800000,1742889600000]],"volumeRatio":0.84907,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"2518852758","title":"和铂医药-B早盘涨近8% 2024年12月初至今累计涨幅已超580%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518852758","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518852758?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:31","pubTimestamp":1741660260,"startTime":"0","endTime":"0","summary":"　　和铂医药-B早盘继续上涨，2024年12月初至今累计涨幅已超580%。截至发稿，股价上涨7.90%，现报8.06港元，成交额6292.57万港元。　　消息面上，和铂医药宣布正式任命Michael D． Patten担任首席战略官。在担任首席战略官期间，Michael将负责制定并统筹和铂医药全球业务发展战略及开发策略，深度管理、运营并强化公司的全球战略合作伙伴网络及生态圈，聚焦中国以外的高潜力海外市场，并进一步提升和铂医药的全球影响力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-11/doc-inepfzsp8816975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","02142","BK1583"],"gpt_icon":0},{"id":"2518732389","title":"港股异动 | 和铂医药-B(02142)再涨超7% 公司正式任命首席战略官 负责拓展全球业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2518732389","media":"智通财经","labels":["executive","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518732389?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:05","pubTimestamp":1741658714,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B再涨超7%，24年12月初至今累计涨幅已超580%。消息面上，和铂医药宣布正式任命Michael D. Patten担任首席战略官。值得注意的是，和铂医药此前宣布，根据其与科伦博泰就HBM9378/SKB378与Windward Bio AG签订的许可协议，公司已收到相应首付款，包括现金付款及Windward Bio母公司股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02142","BK1583"],"gpt_icon":0},{"id":"2518375637","title":"和铂医药-B盘中异动 急速上涨5.09%报7.850港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518375637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518375637?lang=zh_cn&edition=full","pubTime":"2025-03-11 09:57","pubTimestamp":1741658264,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘09时57分，和铂医药-B股票出现异动，股价急速拉升5.09%。截至发稿，该股报7.850港元/股，成交量449.7万股，换手率0.59%，振幅9.50%。资金方面，该股资金流入1676.9万港元，流出1150.48万港元。和铂医药-B股票所在的生物技术行业中，整体涨幅为0.48%。其相关个股中，和铂医药-B、华领医药-B、康方生物涨幅较大，振幅较大的相关个股有方达控股、和铂医药-B、来凯医药-B，振幅分别为13.46%、9.50%、9.13%。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031109574498a33806&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031109574498a33806&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02142","BK1583"],"gpt_icon":0},{"id":"2518386210","title":"和铂医药-B03月10日获主力加仓642万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518386210","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518386210?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:15","pubTimestamp":1741594523,"startTime":"0","endTime":"0","summary":"03月10日, 和铂医药-B股价涨10.34%，报收7.47元，成交金额1.01亿元，换手率1.81%，振幅10.64%，量比1.46。和铂医药-B今日主力资金净流入642万元，连续5日净流入，上一交易日主力净流入219万元。该股近5个交易日上涨35.82%，主力资金累计净流入1828万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2222万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310165639a269b83e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310165639a269b83e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","02142","BK1161"],"gpt_icon":0},{"id":"2518268942","title":"和铂医药-B：股价四连涨，获 9.7 亿美元许可费","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268942","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518268942?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:03","pubTimestamp":1741575825,"startTime":"0","endTime":"0","summary":"截至发稿，其股价上涨 9.75%，报 7.43 港元，成交额 4774.62 万港元。近日，和铂医药宣布，根据与科伦博泰就 HBM9378/SKB378 与 WindwardBioAG 签订的许可协议，公司已收到相应首付款，包括现金付款及 WindwardBio 母公司股权。1 月 10 日签订的许可协议显示，WindwardBio 获 HBM9378/SKB378 在全球范围内研究、开发、生产和商业化的独家授权。和铂医药和科伦博泰有权获总计高达 9.7 亿美元的首付款和里程碑付款，以及基于净销售额的个位数至双位数百分比的分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031011163198a207c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031011163198a207c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1583","02142"],"gpt_icon":0},{"id":"2518386254","title":"和铂医药-B早盘涨近10% 年内股价累计涨逾3倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2518386254","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518386254?lang=zh_cn&edition=full","pubTime":"2025-03-10 10:21","pubTimestamp":1741573260,"startTime":"0","endTime":"0","summary":"　　和铂医药-B早盘继续上涨，暂现四连涨，年内股价累计涨近3倍。截至发稿，股价上涨9.75%，现报7.43港元，成交额4774.62万港元。　　和铂医药近日宣布，根据其与科伦博泰就HBM9378/SKB378与Windward Bio AG签订的许可协议，公司已收到相应首付款，包括现金付款及Windward Bio母公司股权。根据1月10日签订的许可协议，Windward Bio获得HBM9378/SKB378在全球范围内进行研究、开发、生产和商业化的独家授权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-10/doc-inepcsmv3830663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"2518259175","title":"港股异动 | 和铂医药-B(02142)涨超9% 年内股价累涨近3倍 已收到Windward Bio授权协议首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2518259175","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518259175?lang=zh_cn&edition=full","pubTime":"2025-03-10 09:59","pubTimestamp":1741571980,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B涨超9%，年内股价累涨近3倍。消息面上，和铂医药近日宣布，根据其与科伦博泰就HBM9378/SKB378与Windward Bio AG签订的许可协议，公司已收到相应首付款，包括现金付款及Windward Bio母公司股权。根据1月10日签订的许可协议，Windward Bio获得HBM9378/SKB378在全球范围内进行研究、开发、生产和商业化的独家授权。和铂医药此前发布盈喜，预期截至2024年12月31日止年度的溢利将介于人民币730万元至2200万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02142","BK1583","BK1574"],"gpt_icon":0},{"id":"2517076419","title":"和铂医药-B盘中异动 股价大涨5.02%报6.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517076419","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517076419?lang=zh_cn&edition=full","pubTime":"2025-03-06 13:01","pubTimestamp":1741237292,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘13时01分，和铂医药-B股票出现波动，股价快速上涨5.02%。截至发稿，该股报6.280港元/股，成交量660.5万股，换手率0.87%，振幅4.68%。资金方面，该股资金流入1951.4万港元，流出1642.73万港元。和铂医药-B股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，迈博药业-B、创胜集团-B、帝王国际投资涨幅较大，振幅较大的相关个股有迈博药业-B、帝王国际投资、创胜集团-B，振幅分别为75.76%、48.28%、24.84%。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306130132a261db10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306130132a261db10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2517093909","title":"和铂医药-B盘中涨超4% 收到Windward Bio授权协议首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2517093909","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517093909?lang=zh_cn&edition=full","pubTime":"2025-03-06 11:50","pubTimestamp":1741233000,"startTime":"0","endTime":"0","summary":"　　和铂医药-B盘中涨超4%，截至发稿，股价上涨3.34%，现报6.18港元，成交额3817.96万港元。　　和铂医药宣布，根据其与科伦博泰就HBM9378/SKB378与Windward Bio AG签订的许可协议，公司已收到相应首付款，包括现金付款及Windward Bio母公司股权。根据2025年1月10日签订的许可协议，Windward Bio获得HBM9378/SKB378在全球范围内进行研究、开发、生产和商业化的独家授权。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-06/doc-inensrzp6938284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2517390640","title":"和铂医药签署独家协议 收到相应首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2517390640","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517390640?lang=zh_cn&edition=full","pubTime":"2025-03-06 11:19","pubTimestamp":1741231199,"startTime":"0","endTime":"0","summary":"3月6日，和铂医药-B（02142）发布公告，公司已根据与WindwardBioAG签署的独家授权协议，收到相应的首付款，包括现金付款及WindwardBio母公司的股权。此首付款的到账将进一步增强公司的现金储备。根据公告，协议于2025年1月10日签署，合作方包括四川科伦博泰生物医药股份有限公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338318139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2517903694","title":"港股异动 | 和铂医药-B(02142)涨超4% 收到Windward Bio授权协议首付款 全年现金利润达2.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903694","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517903694?lang=zh_cn&edition=full","pubTime":"2025-03-06 10:38","pubTimestamp":1741228712,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B涨超4%，截至发稿，涨4.52%，报6.25港元，成交额2454.87万港元。消息面上，和铂医药宣布，根据其与科伦博泰就HBM9378/SKB378与Windward Bio AG签订的许可协议，公司已收到相应首付款，包括现金付款及Windward Bio母公司股权。此前，和铂医药发盈喜，预期截至2024年12月31日止年度的溢利将介于人民币730万元至2200万元。期内，公司的现金溢利达到人民币2.20亿元的历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","02142","BK1161"],"gpt_icon":0},{"id":"2517397662","title":"和铂医药-B(02142.HK)：收到与WINDWARD BIO AG关于HBM9378/SKB378授权协议的首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2517397662","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517397662?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:07","pubTimestamp":1741219650,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨和铂医药-B(02142.HK)发布公告，公司及科伦博泰生物-B(06990.HK)作为授权方与Windward Bio AG (“Windward Bio”)作为获授权方就HBM9378/SKB378订立独家授权协议。公司已根据协议收到相应首付款，包括现金付款及Windward Bio母公司的股权。该首付款的到账将进一步充盈公司的现金储备。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06080748552971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AG","BIO","BK4588","BK4585","BK1583","BK1161","LU1169589451.USD","BK4210","LU1169590202.USD","BK1574","02142","BK4121"],"gpt_icon":0},{"id":"2517726968","title":"港股异动 | 和铂医药-B(02142)再涨超6% 公司全年现金利润达2.2亿元 孵化公司HBMAT达成全球战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2517726968","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517726968?lang=zh_cn&edition=full","pubTime":"2025-03-05 14:31","pubTimestamp":1741156286,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B再涨超6%，截至发稿，涨5.85%，报5.79港元，成交额3210.06万港元。消息面上，和铂医药近期发盈喜，预期截至2024年12月31日止年度的溢利将介于人民币730万元至2200万元。期内，公司的现金溢利达到人民币2.20亿元的历史新高。和铂医药近期公布，公司孵化的创新型生物技术公司HBMAT宣布与一家业务合作伙伴达成战略合作与许可协议，共同推进针对多种疾病的新型促肾上腺皮质激素释放激素靶向疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","02142","BK1574"],"gpt_icon":0},{"id":"2517495748","title":"和铂医药-B盘中异动 急速拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517495748","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517495748?lang=zh_cn&edition=full","pubTime":"2025-03-05 13:44","pubTimestamp":1741153472,"startTime":"0","endTime":"0","summary":"2025年03月05日下午盘13时44分，和铂医药-B股票出现波动，股价快速拉升5.12%。截至发稿，该股报5.750港元/股，成交量411.1万股，换手率0.54%，振幅6.76%。和铂医药-B股票所在的生物技术行业中，整体涨幅为0.81%。其相关个股中，腾盛博药-B、康宁杰瑞制药-B、和誉-B涨幅较大，振幅较大的相关个股有歌礼制药-B、北海康成-B、腾盛博药-B，振幅分别为32.92%、19.60%、16.85%。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305134432989ca51c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305134432989ca51c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2516691046","title":"和铂医药-B盘中异动 急速下跌5.09%报5.220港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516691046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516691046?lang=zh_cn&edition=full","pubTime":"2025-03-04 09:38","pubTimestamp":1741052284,"startTime":"0","endTime":"0","summary":"2025年03月04日早盘09时38分，和铂医药-B股票出现异动，股价大幅下挫5.09%。截至发稿，该股报5.220港元/股，成交量56.9万股，换手率0.08%，振幅3.45%。资金方面，该股资金流入82.397万港元，流出195.183万港元。和铂医药-B股票所在的生物技术行业中，整体跌幅为2.63%。其相关个股中，科笛-B、荃信生物-B、和誉-B涨幅较大，振幅较大的相关个股有科笛-B、同源康医药-B、乐普生物-B，振幅分别为12.21%、9.66%、9.63%。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304093804989aba36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304093804989aba36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2516957594","title":"港股异动 | 和铂医药-B(02142)涨超5% 孵化公司签署CRH疗法合作协议 机构称全人源仅重链平台价值稀缺","url":"https://stock-news.laohu8.com/highlight/detail?id=2516957594","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516957594?lang=zh_cn&edition=full","pubTime":"2025-03-03 11:42","pubTimestamp":1740973338,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B早盘涨超5%，截至发稿，涨3.85%，报5.4港元，成交额2276.23万港元。消息面上，和铂医药近期公布，公司孵化的创新型生物技术公司HBMAT已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素的新型疗法。天风证券指出，和铂医药是一家处于临床开发阶段的全球创新药公司，对标Teneobio等抗体开发平台，和铂的全人源仅重链平台价值稀缺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1267930573.SGD","LU1093756168.USD","LU1035777561.USD","LU2041044095.USD","LU2463526074.USD","CRH","LU0942090050.USD","LU1039938227.USD","LU0128525929.USD","02142","BK4011","LU0310800379.SGD","LU1880398471.USD","BK1161","LU2092937221.SGD","LU0708994859.HKD","LU1019632923.USD","LU1506573853.SGD","LU1093756325.SGD","LU2360108059.USD","BK1583","BK1574","LU1863844665.USD","LU1291149836.SGD","LU1880398554.USD","LU1019634622.SGD","LU1863844749.USD","LU0238689110.USD","LU2298321311.HKD","LU0029864427.USD","GB00BDT5M118.USD","LU0314106906.USD","LU0868494708.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2516052209","title":"和铂医药-B盘中异动 股价大涨5.00%报5.460港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516052209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516052209?lang=zh_cn&edition=full","pubTime":"2025-03-03 09:59","pubTimestamp":1740967164,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘09时59分，和铂医药-B股票出现波动，股价大幅拉升5.00%。截至发稿，该股报5.460港元/股，成交量193.8万股，换手率0.26%，振幅5.19%。资金方面，该股资金流入463.783万港元，流出516.631万港元。最近的财报数据显示，该股实现营业收入1.85亿港元，净利润1,111.95万港元，每股收益数据暂无，毛利1.76亿港元，市盈率23.21倍。和铂医药-B股票所在的生物技术行业中，整体跌幅为0.95%。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303095924a25c4f1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303095924a25c4f1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02142","BK1583"],"gpt_icon":0},{"id":"2516939315","title":"多家港股创新药企开年股价翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2516939315","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516939315?lang=zh_cn&edition=full","pubTime":"2025-03-02 10:18","pubTimestamp":1740881939,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","02142","HSCEI","159992","BK1161","BK1574","06978","BK1587","BK1585","YANG","02171","159718","HSTECH","07226"],"gpt_icon":0},{"id":"2514005485","title":"和铂医药首个NewCo实现部分退出，股价近三个月涨超300%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514005485","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514005485?lang=zh_cn&edition=full","pubTime":"2025-02-26 14:39","pubTimestamp":1740551996,"startTime":"0","endTime":"0","summary":"和铂医药创始人、董事长兼首席执行官王劲松称，该交易的完成也标志着和铂医药孵化的首个全球NewCo实现部分退出。和铂医药并未披露本次交易的合作伙伴具体信息。今年1月10日，和铂医药与科伦博泰共同宣布达成了另一起NewCo交易，首付款和里程碑付款总金额最高可达9.7亿美元。近三个月来，和铂医药在诸多利好消息刺激下股价涨幅超300%，并创下自2022年4月7日以来的新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226144038a2547031&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226144038a2547031&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02142","BK1583"],"gpt_icon":0},{"id":"2514261560","title":"和铂医药-B(02142)旗下公司与业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2514261560","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514261560?lang=zh_cn&edition=full","pubTime":"2025-02-26 08:06","pubTimestamp":1740528375,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素的新型疗法。HBM9013/HAT001是该集团开发的一项抗CRH抗体疗程，旨在治疗CRH相关疾病，包括先天性肾上腺增生症及其他疾病。目前，CAH的治疗选择有限，导致对创新疗法的重大未满足医疗需求。HBM9013/HAT001已在下调CRH介导的促肾上腺皮质激素诱导方面显示出强大的临床前疗效，并正在向临床开发推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4011","LU2298321311.HKD","BK1161","LU2092937221.SGD","LU1019634622.SGD","LU0868494617.USD","BK1583","LU0310800379.SGD","LU2041044095.USD","LU0942090050.USD","LU0868494708.USD","LU0238689110.USD","LU1880398554.USD","02142","LU1863844749.USD","LU0029864427.USD","LU1035777561.USD","LU1093756168.USD","LU0708994859.HKD","LU1506573853.SGD","CRH","GB00BDT5M118.USD","LU2463526074.USD","LU1019632923.USD","LU1880398471.USD","LU1093756325.SGD","LU1863844665.USD","LU0128525929.USD","LU1291149836.SGD","LU1267930573.SGD","LU0314106906.USD","BK1574","LU1039938227.USD","LU2360108059.USD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.5073},{"period":"3month","weight":4.7762},{"period":"6month","weight":6.1826},{"period":"1year","weight":4.8169},{"period":"ytd","weight":3.4409}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0182},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.2497},{"period":"1year","weight":0.4489},{"period":"ytd","weight":0.1917}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。其中，巴托利单抗（HBM9161）主要用于免疫性血小板减少症、甲状腺相关性眼病、重症肌无力、视神经脊髓炎谱系疾病等. 特那西普（HBM9036）主要用于干眼病。此外，该公司还研究和开发肿瘤免疫产品管线，包括内部开发的新一代肿瘤免疫资产，针对治疗免疫沙漠型、免疫排斥型及炎症型肿瘤。该公司拥有Harbour Mice平台，该平台能够产生经典的双重链双轻链（H2L2）形式及仅重链（HCAb）形式的全人源单克隆抗体。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.104328},{"month":2,"riseRate":0.2,"avgChangeRate":-0.004171},{"month":3,"riseRate":0.4,"avgChangeRate":0.017771},{"month":4,"riseRate":0.5,"avgChangeRate":0.027757},{"month":5,"riseRate":0.5,"avgChangeRate":0.040975},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069984},{"month":7,"riseRate":0.25,"avgChangeRate":0.010824},{"month":8,"riseRate":0,"avgChangeRate":-0.134459},{"month":9,"riseRate":0.25,"avgChangeRate":-0.098643},{"month":10,"riseRate":0,"avgChangeRate":-0.190485},{"month":11,"riseRate":0.75,"avgChangeRate":0.322177},{"month":12,"riseRate":0.75,"avgChangeRate":0.358142}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}